Eric Crombez
Chief Medical Officer & Executive VPDr. Eric Crombez, M.D., is Director of Epicrispr Biotechnologies, Inc. from March 2025. He is Independent Director at Abeona Therapeutics LLC since August 08, 2024. He serves as Chief Medical Officer & Executive VP at Ultragenyx Pharmaceutical Inc. since May 01, 2023. He serves as an Independent Director of Abeona Therapeutics Inc. since August 2024. He is the FDA Alternate Industry Representative on the Cellular, Tissue and Gene Therapies Advisory Committee since January 2020. Dr. Crombez served as the Chief Medical Officer of Dimension Therapeutics, Inc. since December 1, 2014. Dr. Crombez has Dimension extensive experience and expertise in the development and execution of clinical development programs for rare genetic disorders. He serves as Member of Scientific Advisory Board of STRM.BIO INCORPORATED. While at Shire, Dr. Crombez served as medical director and then senior medical director of Global Clinical Development. He played a key role in the advancement of the pivotal trials and global marketing registration submissions for VPRIV(TM) (velaglucerase alfa for injection), Shire's enzyme replacement therapy for the treatment of Type 1 Gaucher disease which is now available in the US and more than 40 other countries. Dr. Crombez also played a key role in the translation of Shire's intrathecal enzyme replacement therapy program for Metachromatic Leukodystrophy from bench research into clinical trials. Previously, Dr. Crombez was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Crombez is a board-certified clinical geneticist and has authored more than 40 peer-reviewed articles, book chapter and presentation abstracts. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor and his M.D. degree from Wayne State University School of Medicine, Detroit. Dr. Crombez completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine.
Positions
- Company NameUltragenyx Pharmaceutical Inc.Stock CodeRAREPositionChief Medical Officer & Executive VPColleagues
- EDEmil D. KakkisFounder, President, CEO & Director
- DGDaniel G. WelchIndependent Non-Executive Chairman
- HHHoward HornExecutive VP of Corporate Strategy & CFO
- KHKarah Herdman ParschauerChief Legal Officer & Executive VP of Corporate Affairs
- EHErik HarrisExecutive VP & Chief Commercial Officer
- MKMatthew K. FustIndependent Director
- MAMichael A. NarachiIndependent Director
- SSShehnaaz SulimanIndependent Director
